A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

NCT04324476 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

DRUG: Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine

Sponsor

Jiangsu Cancer Institute & Hospital